Literature DB >> 20687785

Lacosamide for pain.

Gary McCleane1.   

Abstract

IMPORTANCE OF THE FIELD: Neuropathic pain remains a condition that is difficult to treat and with which therapeutic failure is not uncommon. The need for new and effective drugs to treat neuropathic pain remains strong. AREAS COVERED IN THIS REVIEW: The available preclinical and clinical data for the pain relieving effect of lacosamide have been examined using the papers published and referenced on Medline between 1990 and present. WHAT THE READER WILL GAIN: It is hoped that readers will gain an insight into the use of this novel analgesic agent in human clinical pain. TAKE HOME MESSAGE: The data relating to the pain relieving effect of lacosamide are sparse. The majority of the published human data relate to the use of lacosamide for the treatment of painful diabetic neuropathy where the extent of pain relief produced has not been deemed sufficient to warrant an application for a product license for this indication. That said, it is suggested that there remains merit in further investigation of this drug for other neuropathic pain conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687785     DOI: 10.1517/13543784.2010.511174

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  5 in total

1.  IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG).

Authors:  Keith G Phillips; Rolf-Detlef Treede; André Mouraux; Petra Bloms-Funke; Irmgard Boesl; Ombretta Caspani; Sonya C Chapman; Giulia Di Stefano; Nanna Brix Finnerup; Luis Garcia-Larrea; Marcus Goetz; Anna Kostenko; Bernhard Pelz; Esther Pogatzki-Zahn; Karin Schubart; Alexandre Stouffs; Andrea Truini; Irene Tracey; Iñaki F Troconiz; Johannes Van Niel; Jose Miguel Vela; Katy Vincent; Jan Vollert; Vishvarani Wanigasekera; Matthias Wittayer
Journal:  Trials       Date:  2021-06-17       Impact factor: 2.279

2.  Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial.

Authors:  Malin E Carmland; Melissa Kreutzfeldt; Jakob V Holbech; Niels T Andersen; Troels S Jensen; Flemming W Bach; Søren H Sindrup; Nanna B Finnerup
Journal:  Trials       Date:  2019-10-11       Impact factor: 2.279

3.  IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET).

Authors:  Zahra Nochi; Hossein Pia; Petra Bloms-Funke; Irmgard Boesl; Ombretta Caspani; Sonya C Chapman; Francesca Fardo; Bernd Genser; Marcus Goetz; Anna V Kostenko; Caterina Leone; Thomas Li; André Mouraux; Bernhard Pelz; Esther Pogatzki-Zahn; Andreas Schilder; Erik Schnetter; Karin Schubart; Alexandre Stouffs; Irene Tracey; Iñaki F Troconiz; Andrea Truini; Johannes Van Niel; Jose Miguel Vela; Katy Vincent; Jan Vollert; Vishvarani Wanigasekera; Matthias Wittayer; Hatice Tankisi; Nanna B Finnerup; Keith G Phillips; Rolf-Detlef Treede
Journal:  Trials       Date:  2022-02-19       Impact factor: 2.279

4.  IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity.

Authors:  Caterina Leone; Giulia Di Stefano; Keith G Phillips; Andrea Truini; Rolf-Detlef Treede; Giuseppe Di Pietro; Petra Bloms-Funke; Irmgard Boesl; Ombretta Caspani; Sonya C Chapman; Nanna Brix Finnerup; Luis Garcia-Larrea; Tom Li; Marcus Goetz; André Mouraux; Bernhard Pelz; Esther Pogatzki-Zahn; Andreas Schilder; Erik Schnetter; Karin Schubart; Irene Tracey; Inaki F Troconiz; Hans Van Niel; Jose Miguel Vela Hernandez; Katy Vincent; Jan Vollert; Vishvarani Wanigasekera; Matthias Wittayer
Journal:  Trials       Date:  2022-09-05       Impact factor: 2.728

5.  Effective Modulation by Lacosamide on Cumulative Inhibition of INa during High-Frequency Stimulation and Recovery of INa Block during Conditioning Pulse Train.

Authors:  Po-Ming Wu; Yu-Ching Lin; Chi-Wu Chiang; Hsin-Yen Cho; Tzu-Hsien Chuang; Meng-Cheng Yu; Sheng-Nan Wu; Yi-Fang Tu
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.